Pentoxifylline_NN
for_IN
the_DT
treatment_NN
of_IN
infection_NN
with_IN
human_JJ
immunodeficiency_NN
virus_NN
._.

Cytokine_NN
dysregulation_NN
in_IN
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
-LRB-_-LRB-
HIV-1_NN
-RRB-_-RRB-
infection_NN
has_VBZ
been_VBN
documented_VBN
in_IN
numerous_JJ
studies_NNS
and_CC
has_VBZ
been_VBN
cited_VBN
as_IN
an_DT
important_JJ
component_NN
in_IN
the_DT
pathogenesis_NN
of_IN
this_DT
retroviral_JJ
infection_NN
._.

Pharmacological_JJ
modification_NN
of_IN
cytokine_NN
dysregulation_NN
,_,
therefore_RB
,_,
has_VBZ
been_VBN
suggested_VBN
as_IN
a_DT
therapeutic_JJ
modality_NN
for_IN
HIV-1_NN
infection_NN
._.

Dr._NNP
Dezube_NNP
of_IN
Beth_NNP
Israel_NNP
Hospital_NNP
-LRB-_-LRB-
Boston_NNP
-RRB-_-RRB-
concisely_RB
reviews_VBZ
the_DT
state_NN
of_IN
our_PRP$
knowledge_NN
regarding_VBG
the_DT
effects_NNS
of_IN
pentoxifylline_NN
on_IN
expression_NN
of_IN
tumor_NN
necrosis_NN
factor-alpha_NN
,_,
a_DT
cytokine_NN
known_VBN
to_TO
influence_VB
HIV-1_NN
replication_NN
and_CC
to_TO
play_VB
a_DT
possible_JJ
role_NN
in_IN
the_DT
clinical_JJ
manifestations_NNS
of_IN
advanced_JJ
infection_NN
with_IN
this_DT
virus_NN
._.

Pentoxifylline_NN
,_,
a_DT
trisubstituted_JJ
xanthine_NN
derivative_NN
,_,
has_VBZ
been_VBN
used_VBN
to_TO
decrease_VB
blood_NN
viscosity_NN
and_CC
is_VBZ
reasonably_RB
well_RB
tolerated_VBN
by_IN
most_JJS
recipients_NNS
of_IN
the_DT
drug_NN
._.

Results_NNS
of_IN
preliminary_JJ
studies_NNS
,_,
many_JJ
of_IN
which_WDT
were_VBD
conducted_VBN
by_IN
Dr._NNP
Dezube_NNP
,_,
suggest_VBP
that_IN
use_NN
of_IN
this_DT
agent_NN
in_IN
combination_NN
with_IN
antiretroviral_JJ
compounds_NNS
may_MD
prove_VB
useful_JJ
in_IN
the_DT
treatment_NN
of_IN
patients_NNS
with_IN
HIV-1_NN
infection_NN

